Table 2. Comparison of clinicopathological characteristics between mass-forming ICC and atypical HCC.
| Clinical parameters | Mass-forming ICC (n=53) | Atypical HCC (n=76) | χ2/t | P value |
|---|---|---|---|---|
| Age (years) | 60.96±8.04 | 57.67±11.65 | 1.898 | 0.060 |
| Sex | 0.674 | 0.412 | ||
| Male | 43 (81.1) | 57 (75.0) | ||
| Female | 10 (18.9) | 19 (25.0) | ||
| Child-Pugh scores | 1.422 | 0.233 | ||
| Grade A | 41 (77.4) | 65 (85.5) | ||
| Grade B | 12 (22.6) | 11 (14.5) | ||
| AFP (ng/mL) | 19.631 | <0.001 | ||
| ≤7.0 | 37 (69.8) | 23 (30.3) | ||
| >7.0 | 16 (30.2) | 53 (69.7) | ||
| CA19-9 (U/mL) | 44.347 | <0.001 | ||
| ≤37 | 12 (22.6) | 62 (81.6) | ||
| >37 | 41 (77.4) | 14 (18.4) | ||
| CEA (ng/mL) | 6.752 | 0.009 | ||
| ≤5 | 36 (67.9) | 66 (86.8) | ||
| >5 | 17 (32.1) | 10 (13.2) |
Data are number of patients (percentage) or mean ± standard deviation. The age comparisons were performed using the independent samples t-test. Except where noted, data were compared using the χ2 test. ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma; AFP, alpha fetoprotein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoma embryonic antigen.